Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with Hereditary Angioedema Lead Investing
Ero Copper to Release Third Quarter 2025 Operating and Financial Results on November 4, 2025 Zinc Investing
Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01 Lead Investing
Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations Lead Investing
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 - October 02, 2025 Lead Investing
Astria Therapeutics Now Enrolling HAE Patients in the European Union for the Phase 3 ALPHA-ORBIT Trial Lead Investing
